- 1.Circulation: Cardiovascular Imaging,April 4, 2017, Advances in Cardiovascular Imaging; Safety With Echocardiographic Contrast Agents
Authors: Preetham R. Muskula, MD, Michael L. Main, MD
- 2.Ultrasound International Open, April 2017, Clinical Applications of Contrast-Enhanced Ultrasound in the Pediatric Work-Up of Focal Liver Lesions and Blunt Abdominal Trauma: A Systematic Review
Authors: Nicolaj Grønbæk Laugesen, Christian Pallson Nolsoe, Jacob Rosenberg
- 3.Science Daily,April 4, 2017, Ultrasound and microbubbles flag malignant cancer in humans, says study
Source: Stanford University Medical Center
Circulation: Cardiovascular Imaging
Advances in Cardiovascular Imaging
Safety With Echocardiographic Contrast Agents
April 4, 2017
Authors: Preetham R. Muskula, MD; Michael L. Main, MD
In October 2007, the Food and Drug Administration mandated significant revisions to product labeling for the commercially available echocardiographic contrast agents (ECA) Definity and Optison after spontaneous healthcare provider reports of 4 patient deaths and ≈190 severe cardiopulmonary reactions occurring in close temporal relationship to ECA administration. Since then, multiple large ECA safety studies have been published and have included outpatients, hospitalized patients (including the critically ill), patients undergoing stress echocardiography, and patients with pulmonary hypertension. In addition, the Food and Drug Administration has convened 2 Advisory Committee meetings and the product labels for Optison and Definity have been substantially revised with a softening of safety restrictions.
In this review, we will address the safety of ECA use in patients with serious cardiopulmonary conditions, patients with intracardiac shunts, and special patient populations including pulmonary hypertension, pediatrics, and pregnancy. In addition, we will discuss the confounding role of pseudocomplication in attribution of adverse events during diagnostic testing, the current status of the ECA Black Box Warning, and recommended safety precautions during ECA administration.
Ultrasound International Open
Ultrasound Int Open 2017; 03(01): E2-E7 DOI: 10.1055/s-0042-124502
Clinical Applications of Contrast-Enhanced Ultrasound in the Pediatric Work-Up of Focal Liver Lesions and Blunt Abdominal Trauma: A Systematic Review
Authors: Nicolaj Grønbæk Laugesen1, Christian Pallson Nolsoe2, Jacob Rosenberg3
Affiliations: 1 Neurological, Herlev Hospital, Herlev, Denmark; 2 Ultrasound Section, Department of Gastroenterology, Departmentof Surgery, Herlev Hospital, Herlev, Denmark; 3 Department of Surgery, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
In pediatrics ultrasound has long been viewed more favorably than imaging that exposes patients to radiation and iodinated contrast or requires improved sedation. It is child-friendly and diagnostic capabilities have been with the advent of contrast-enhanced ultrasound (CEUS). The application of CEUS is indeed promising. However, no ultrasound contrast agent manufactured today is registered for pediatric use in Europe. The contrast agent SonoVue® has recently been approved by the FDA under the name of Lumason® to be used in hepatic investigations in adults and children. This article reviews the literature with respect to 2specific applications of CEUS in children: 1) identification of parenchymal injuries following blunt abdominal trauma, and 2) classification of focal liver lesions. Applications were chosen through the CEUS guidelines published by the European Federation of Societies for Ultrasound in Medicine and Biology and World Federation for Ultrasound in Medicine and Biology. Literature was obtained by searching Medline and Pubmed Central (using Pubmed), Scopus database and Embase. CEUS proved to be an effective investigation in the hemodynamically stable child for identifying parenchymal injuries and for the characterization of focal liver lesions. CEUS showed comparable performance to CT and MRI with a specificity of 98 % for identifying benign lesions and a negative predictive value of 100 %. For the applications reviewed here, CEUS holds promising perspectives and can help reduce radiation exposure and use of iodinated contrast agents in pediatrics, thereby potentially reducing complications in routine imaging.
Ultrasound and microbubbles flag malignant cancer in humans, says study
April 4, 2017
Source: Stanford University Medical Center
Jürgen Willmann, MD, a professor of radiology at Stanford, is lead author, and Sanjiv "Sam" Gambhir, MD, PhD, professor and chair of radiology, is the senior author of the study.
Originally published online March 14 in theJournal of Clinical Oncology.
A Stanford-led team of researchers has developed tiny bubbles that bind to malignant tumors, making them visible to ultrasound imaging.
A team led by researchers from the Stanford University School of Medicine has demonstrated a way to diagnose cancer without resorting to surgery, raising the possibility of far fewer biopsies.
For this first-in-humans clinical trial, women with either breast or ovarian tumors were injected intravenously with microbubbles capable of binding to and identifying cancer.
For the study, 24 women with ovarian tumors and 21 women with breast tumors were intravenously injected with the microbubbles. Clinicians used ordinary ultrasound to image the tumors for about a half-hour after injection. The high-tech bubbles clustered in the blood vessels of tumors that were malignant, but not in those that were benign.
The ultrasound imaging of patients’ bubble-labeled tumors was followed up with biopsies and pathology studies that confirmed the accuracy of the diagnostic microbubbles
Medical microbubbles are spheres of phospholipids, the same material that makes up the membranes of living cells. The bubbles are 1 to 4 microns in diameter, a little smaller than a red blood cell, and filled with a harmless mixture of perfluorobutane and nitrogen gas.
Ordinary microbubbles have been approved by the Food and Drug Administration and in clinical use for several years now. But such microbubbles, a kind of ultrasound "contrast agent," have only been used to image organs like the liver by displaying the bubbles as they pass through blood vessels. Up to now, the bubbles couldn’t latch onto blood vessels of cancer in patients.
The microbubbles used in this study were designed to bind to a receptor called KDR found on the tumor blood vessels of cancer but not in healthy tissue. Noncancerous cells don’t have such a receptor. Under ultrasound imaging, the labeled microbubbles, called MBKDR, show up clearly when they cluster in a tumor. And since benign breast and ovarian tumors usually lack KDR, the labeled microbubbles mostly passed them by.
In this small, preliminary safety trial, the technique appeared to be both safe and very sensitive, said Willmann, who is chief of the Division of Body Imaging at Stanford. And it also works with ordinary ultrasound equipment. "So, there’s no new ultrasound equipment that needs to be built for that," he said. "You can just use your regular ultrasound and turn on the contrast mode — which all modern ultrasound equipment has."
Willmann said now that the phase-1 trial has shown that the MBKDR contrast agent is safe for patients, his team is moving forward in a larger phase-2 trial. In that trial, the team will measure how well the combination of MBKDRand ultrasound differentiate cancer from noncancer in breast and in ovarian tumors. The team will also try to find out how small a tumor can be imaged using KDR microbubbles. Because the diagnostic approach can, in principle, be used with any kind of cancer that expresses KDR, they plan to image pancreatic cancer tumors as well.
One of the advantages of MBKDR, Willmann said, is that the bubbles remain attached to the tumors for several minutes and as long as half an hour — the longest time tested in the trial. That should give clinicians time to image both breasts or ovaries without having to start over with a new injection of contrast agent.
If all goes as hoped, the KDR microbubbles could improve diagnoses and reduce unnecessary surgeries in women suspected of having breast or ovarian cancer.
"The difficulty with ultrasound right now," Willmann said, "is that it detects a lot of lesions in the breast, but most of them are benign. And that leads to many unnecessary biopsies and surgeries."
The work is an example of Stanford Medicine’s focus on precision health, the goal of which is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.Distinguishing benign from malignant tumors with harmless ultrasound imaging could save millions of patients from biopsies they don’t need, Willman said. "To decrease those unnecessary biopsies and surgeries would be a huge leap forward," he said. "We could make ultrasound a highly accurate screening technology that is relatively low cost, highly available and with no radiation." And since ultrasound technology is accessible almost everywhere, he said, the technology could potentially help patients all over the world.
Other Stanford-affiliated co-authors of the study are assistant professor of radiology Amelie Lutz, MD, and research assistant Keerthi Valluru.
Gambhir is director of the Canary Center for Cancer Early Detection at Stanford, director of the Molecular Imaging Program at Stanford and a member of Stanford Bio-X, the Stanford Cancer Institute, the Stanford Cardiovascular Institute and Stanford ChEM-H. Willmann is a member of Stanford Bio-X, the Molecular Imaging Program and the Canary Center. Lutz is a member of Stanford Bio-X.
Researchers from the Gemelli University Hospital in Rome are also co-authors of the study.
The research was supported by the National Institutes of Health (grants R01CA155289, CCNE-TU54CA151459 and CCNE-TRU54CA119367), the Bracco Group and the Canary Foundation.
1. IAC, Complimentary Webinar-Contrast Enhanced Ultrasound -a joint presentation with IAC, ASE, SDMS and ICUS on March 21st at 1 p.m. ET.
Contrast Enhanced Ultrasound
A Joint Presentation of IAC, ASE, SDMS and ICUS
On Tuesday, March 21st, 2017 at 1 p.m. ET, Steven B. Feinstein, MD, Michael Main, MD and Thomas R. Porter, MD, experts in the field of contrast enhanced ultrasound, will present a live webinar (followed by a Q&A session) entitled Contrast Enhanced Ultrasound. This webinar is a joint presentation of IAC, the American Society of Echocardiography (ASE), the Society of Diagnostic Medical Sonography (SDMS) and the International Contrast Ultrasound Society (ICUS).
How to Register
Click the Register link below. A new window will open to the IAC Webinars site at ProLibraries.com. On the right side of the screen under $0.00, click Register, then View Cart. Next click the Checkout button (cart icon). Then, first-time users will create a new account under 'New Users Register Here' and click Register at the bottom to complete your registration; returning users to this site will go to 'Returning Users' at the far right, log in to your webinar account, and click Login.
Note: This account is for IAC webinars only; it is the account you will use to log in to future IAC webinars. This platform is not associated with your Online Accreditation account. Do not try to log in using that username and password.
About the Webinar
This webinar is designed to:
- Educate participants on the clinical diagnostic applications of Contrast Enhanced Ultrasound
- Educate participants on the clinical and research therapeutic applications of Contrast Enhanced Ultrasound
- Discuss the clinical safety of Contrast Enhanced Ultrasound, including recent product labeling changes
- Dovepress, Feb 22, 2017, Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study Authors: Yi-Xuan Zhao
- ICUS - SAVE THE DATE!, First ICUS CEUS Educational Event - June 17, 2017
Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study
Feb 22, 2017
Authors: Yi-Xuan Zhao, Shuang Liu, Yan-Bing Hu, Yan-Yan Ge, Dong-Mei Lv
Department of Ultrasound, Second Hospital, Jilin University, Changchun, People’s Republic of China
Volume 2017:10 Pages 1123—1129
This study aimed to explore the diagnostic and prognostic values of contrast-enhanced ultrasound (CEUS) in breast cancer. Between September 2009 and October 2011, a total of 143 breast cancer patients and 161 healthy people were selected as case group and control group, respectively. After the identification of lesions by conventional ultrasound, all patients underwent CEUS. The CEUS images were analyzed, and time–intensity curves (TICs) were obtained. Hematoxylin–eosin and immunohistochemistry staining was performed on tissue specimens, according to which the expressions of estrogen receptor (ER), c-erb-B2, p53, and Ki-67 were measured. Multivariate logistic regression analysis was used to compare CEUS and TIC parameters between the two groups. Compared with the control group, cancer patients showed high enhancement, heterogeneous enhancement or defects in the central region, expansion of lesion diameter after enhancement and crab-like blur lesion edges. The peak intensity (PI), relative start time of enhancement, relative PI, and relative area under the curve in the case group were significantly higher than those in the control group. Logistic analysis showed that the uniformity of enhancement, expansion of lesion diameter, and relative PI were significant diagnostic parameters of breast cancer, with area under the curve being 0.798, 0.776, and 0.919, respectively. There were strong associations between CEUS characteristics and expressions of prognostic factors in breast cancer: the heterogeneous enhancement was common in c-erb-B2-positive tumors; the centripetal enhancement occurred more in ER-negative tumors; perforator vessels were often seen in tumors at high histological grade; perfusion defects were common in ER-negative, c-erb-B2-positive, and Ki-67-positive tumors. CEUS is a useful tool for the early diagnosis and prognosis of breast cancer.
ICUS SAVE THE DATE!
First ICUS CEUS Educational Event
Attend this exciting, one day ICUS educational event, providing information and instruction to novices in the field of CEUS.
Date: June 17, 2017
Location: Calgary AB, CANADA
Details and Registration Information to follow.
Get started on CEUS and learn about microbubble contrast agents, how they work, their safety, and their indications for liver and kidney mass characterization, and more.
Live CEUS demonstrations and hands on equipment exposure will include the latest from GE, Mindray, Philips, Samsung, Siemens and Toshiba.
And afterwards…..visit the beautiful Banff National Park, which has free entry for 2017 to celebrate Canada's 150th Anniversary!